Get the Stockscreener App
13.72
1.33%
0.18
Day One Biopharmaceuticals Inc Stock (DAWN) Latest News
Why Is Day One Biopharmaceuticals Inc. (DAWN) Among the Best Up and Coming Stocks to Buy According to Analysts? - Insider Monkey
10 Best Up and Coming Stocks To Buy According to Analysts - Insider Monkey
Glioma Market Size in the 7MM is approximately USD 1,000 million in 2023, estimated DelveInsight - The Globe and Mail
What Analysts Were Expecting After Day One Biopharmaceuticals Inc (NASDAQ: DAWN) fell -2.06% - Stocks Register
When the Price of (DAWN) Talks, People Listen - Stock Traders Daily
Day One Biopharmaceuticals announces R&D leadership change By Investing.com - Investing.com Australia
Day One Biopharmaceuticals announces R&D leadership change - Investing.com India
Day One Biopharmaceuticals announces executive retirement By Investing.com - Investing.com UK
Day One Announces Retirement of Dr. Samuel Blackman, Co-Founder and Head of Research & Development - GlobeNewswire
Wall Street Analysts See a 136.83% Upside in Day One Biopharmaceuticals (DAWN): Can the Stock Really Move This High? - MSN
Day one Biopharmaceuticals COO sells shares worth $34,372 By Investing.com - Investing.com South Africa
Day One Biopharmaceuticals CEO sells $139,420 in stock - Investing.com
Day one Biopharmaceuticals COO sells shares worth $34,372 - Investing.com
Day One Biopharmaceuticals CEO sells $139,420 in stock By Investing.com - Investing.com UK
First Turn Management LLC Invests $13.20 Million in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - MarketBeat
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Sees Large Increase in Short Interest - MarketBeat
First Week of July 2025 Options Trading For Day One Biopharmaceuticals (DAWN) - Nasdaq
Day One to Participate in the Piper Sandler 36th Annual Healthcare Conference - The Manila Times
Day One Biopharmaceuticals to Present at Piper Sandler Healthcare Conference | DAWN Stock News - StockTitan
59,259 Shares in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Bought by GSA Capital Partners LLP - MarketBeat
(DAWN) Trading Advice - Stock Traders Daily
TimesSquare Capital Management LLC Has $25.46 Million Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - MarketBeat
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Insider Sells $180,257.35 in Stock - MarketBeat
FMR LLC Bolsters Position in Day One Biopharmaceuticals Inc - GuruFocus.com
Exploring Three High Growth Tech Stocks in the United States - Simply Wall St
Day One Biopharmaceuticals (NASDAQ:DAWN) Upgraded at TD Cowen - MarketBeat
Day one biopharmaceuticals head of R&D sells $8,010 in stock By Investing.com - Investing.com Canada
Day one biopharmaceuticals head of R&D sells $8,010 in stock - Investing.com
Forecast: Analysts Think Day One Biopharmaceuticals, Inc.'s (NASDAQ:DAWN) Business Prospects Have Improved Drastically - Simply Wall St
Bullish: Analysts Just Made A Huge Upgrade To Their Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Forecasts - Yahoo Finance
Equities Analysts Issue Forecasts for DAWN Q1 Earnings - MarketBeat
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
We Think Day One Biopharmaceuticals (NASDAQ:DAWN) Can Easily Afford To Drive Business Growth - Yahoo Finance
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Q3 2024 Earnings Call Transcript - Insider Monkey
Day One Biopharmaceuticals’ Revenue at Risk: Heavy Dependence on Few Key Customers - TipRanks
(DAWN) Proactive Strategies - Stock Traders Daily
Day One Biopharmaceuticals (NASDAQ:DAWN) Issues Earnings Results, Beats Estimates By $0.58 EPS - MarketBeat
Day One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap Up After Earnings Beat - MarketBeat
Pre-Market Trading Boosts Day One (DAWN) Amid High OJEMDA Demand - Stocks Telegraph
Day One Biopharmaceuticals (NASDAQ:DAWN) Given "Buy" Rating at HC Wainwright - MarketBeat
ChromaDex Q3 2024 Earnings Preview - MSN
Day One Biopharmaceuticals, Inc. (DAWN) Surpasses Q3 Earnings and Revenue Estimates - MSN
Day One Biopharmaceuticals Reports Strong Q3 Growth - TipRanks
Day One Biopharmaceuticals earnings beat by $0.99, revenue topped estimates - Investing.com UK
DAWNDay One Biopharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Day One Reports Third Quarter 2024 Financial Results and Corporate Progress - The Manila Times
Day One Biopharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Day One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap UpStill a Buy? - MarketBeat
Day One Biopharma shares retain overweight rating on ojemda drug usage - Investing.com UK
Day One Biopharmaceuticals (DAWN) to Release Earnings on Wednesday - MarketBeat
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):